Showing 1 – 5 of 5
Relevance | Newest | Oldest |
  • Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer

    Abstract Full Text
    open access
    JAMA Netw Open. 2020; 3(4):e203277. doi: 10.1001/jamanetworkopen.2020.3277

    This cohort study examines the association of Medicaid coverage with survival, compared with other insurance statuses, among patients with small cell lung cancer.

  • Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer

    Abstract Full Text
    free access
    JAMA Oncol. 2019; 5(11):1597-1604. doi: 10.1001/jamaoncol.2019.2809

    This phase 1/2 single-arm trial examined toxic effects, local control, and overall survival rates after chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease for patients with unresectable locally advanced esophageal cancer.

  • Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Component of a Phase 2/3 Trial

    Abstract Full Text
    free access has multimedia
    JAMA Oncol. 2019; 5(6):872-878. doi: 10.1001/jamaoncol.2019.0192

    This randomized phase 2 noninferiority trial assessed the efficacy of high-dose, single-fraction stereotactic radiation therapy vs standard multifraction radiation therapy for pain relief in patients with mostly nonspine bone metastases.

  • Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer

    Abstract Full Text
    open access online only
    JAMA Netw Open. 2018; 1(4):e181390. doi: 10.1001/jamanetworkopen.2018.1390

    This cohort study examines long-term outcomes for patients with isolated local recurrence or isolated regional recurrence after stereotactic ablative radiotherapy for early-stage non–small cell lung cancer with the aim of informing treatment decision making.

  • Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer

    Abstract Full Text
    free access online only
    JAMA Oncol. 2018; 4(8):e174504. doi: 10.1001/jamaoncol.2017.4504

    This study uses data from the National Cancer Database to estimate utilization rates and factors associated with chemotherapy and radiation therapy delivery for limited-stage small cell lung cancer.